NasdaqGS - Nasdaq Real Time Price USD

Viatris Inc. (VTRS)

Compare

11.67

-0.29

(-2.42%)

At close: January 10 at 4:00:00 PM EST

11.80

+0.13

+(1.11%)

After hours: January 10 at 6:39:15 PM EST

Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025. The company's presentation and fireside chat will begin at 8:15 a.m. PT / 11:15 a.m. ET.

PR Newswire 4 days ago

VTRS
-2.42%
US FDA restricts imports of some Viatris drugs made at India facility

The FDA has issued a warning letter to Viatris related to its drug manufacturing facility in Indore in the central Indian state of Madhya Pradesh, the company said, without disclosing the specifics of the warning. The 11 products will no longer be accepted into the U.S. until the warning letter is lifted, Viatris said in a statement.

Reuters 18 days ago

VTRS
-2.42%
What Makes Viatris (VTRS) a Favorite Stock for Billionaire David Einhorn?

We recently compiled a list of the 10 Best Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other best stocks to buy according to Billionaire David Einhorn. The markets are broken and getting worse. That’s the stance […]

Insider Monkey 23 days ago

VTRS
-2.42%
GLRE
Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology

Viatris Inc. (NASDAQ: VTRS) today announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE). The results, published in Lancet Rheumatologyi, showed cenerimod 4 mg demonstrated clinically meaningful and sustained improvement from baseline on multiple measures of SLE disease activity compared to placebo, in addition to stable background SLE therapy. Cenerimod was shown to be well tol

PR Newswire 24 days ago

VTRS
-2.42%
Viatris fined in Morocco over merger notification, sources say

U.S. pharmaceutical giant Viatris Inc has been fined 7.58 million dirhams ($760,000) by Morocco's competition regulator for failing to notify it regarding its merger, two official sources said on Thursday. Viatris was formed by the merger of Mylan, which has a subsidiary in Morocco, and Pfizer's Upjohn business in 2020. The fine, equivalent to 2.5% Viatris' revenue in Morocco last year, has already been paid to the Moroccan treasury, the sources said, requesting anonymity.

Reuters last month

VTRS
-2.42%
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y

TBPH beats third-quarter estimates for both sales and earnings. Increased collaboration revenues from Viatris drive year-over-year top-line performance.

Zacks last month

TBPH

VTRS
-2.42%
ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m

ALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, Australia, and China.

Pharmaceutical Technology last month

SPRY

ALK-B.CO

GLDAF
Viatris Inc (VTRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ...

Viatris Inc (VTRS) reports solid financial performance with a focus on innovation and debt management, despite challenges in certain markets.

GuruFocus.com 2 months ago

VTRS
-2.42%
S&P 500 Gains and Losses Today: Index Ticks Higher as Fed Trims Benchmark Rate

The S&P 500 added 0.7% on Thursday Nov. 7, 2024, as the Fed announced a quarter-point interest-rate cut, in line with market expectations.

Investopedia 2 months ago

^GSPC

MTCH

EPAM
Viatris Beats on Q3 Earnings and Revenues, Lowers Profit Guidance

VTRS Q3 earnings and sales beat estimates. New products perform well.

Zacks 2 months ago

VTRS
-2.42%
Viatris (VTRS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks 2 months ago

VTRS
-2.42%
Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates

Viatris (VTRS) delivered earnings and revenue surprises of 10.29% and 1.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

VTRS
-2.42%
Viatris: Q3 Earnings Snapshot

On a per-share basis, the Canonsburg, Pennsylvania-based company said it had profit of 8 cents. Earnings, adjusted for one-time gains and costs, were 75 cents per share. The results beat Wall Street expectations.

Associated Press Finance 2 months ago

VTRS
-2.42%
Viatris Reports Third Quarter Financial Results for 2024

Total Revenues of $3.8 Billion and Operational Revenue Growth of ~3% on a Divestiture-Adjusted Basis Demonstrate Strength of Company's Base Business[1]

PR Newswire 2 months ago

VTRS
-2.42%
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?

Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.

Zacks 2 months ago

NVO

MRNA

TEVA
Viatris Announces Third Quarter 2024 Dividend

Viatris Inc. (NASDAQ: VTRS) today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 13, 2024, to shareholders of record as of the close of business on November 22, 2024.

PR Newswire 2 months ago

VTRS
-2.42%
Viatris to Report Q3 Earnings: What's in the Cards?

VTRS' Q3 results are likely to gain from new product launches in all major geographies.

Zacks 2 months ago

VTRS
-2.42%
Unveiling Viatris (VTRS) Q3 Outlook: Wall Street Estimates for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for Viatris (VTRS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

Zacks 2 months ago

VTRS
-2.42%
Viatris Named to Forbes' World's Top Companies for Women 2024 List

Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' World's Top Companies for Women 2024 List. This award is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider.

PR Newswire 2 months ago

VTRS
-2.42%
Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the company will participate in two upcoming healthcare conferences.

PR Newswire 2 months ago

VTRS
-2.42%

Performance Overview

Return	VTRS	S&P 500
YTD	-5.74%	-1.35%
1-Year	+4.74%	+22.51%
3-Year	-9.93%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Viatris Inc. (VTRS)

Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference

US FDA restricts imports of some Viatris drugs made at India facility

What Makes Viatris (VTRS) a Favorite Stock for Billionaire David Einhorn?

Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology

Viatris fined in Morocco over merger notification, sources say

Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y

ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m

Viatris Inc (VTRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ...

S&P 500 Gains and Losses Today: Index Ticks Higher as Fed Trims Benchmark Rate

Viatris Beats on Q3 Earnings and Revenues, Lowers Profit Guidance

Viatris (VTRS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates

Viatris: Q3 Earnings Snapshot

Viatris Reports Third Quarter Financial Results for 2024

What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?

Viatris Announces Third Quarter 2024 Dividend

Viatris to Report Q3 Earnings: What's in the Cards?

Unveiling Viatris (VTRS) Q3 Outlook: Wall Street Estimates for Key Metrics

Viatris Named to Forbes' World's Top Companies for Women 2024 List

Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference

Performance Overview